SLU-PP-332 (60 capsules, 250MCG)

What is SLU-PP-332 (60 capsules, 250MCG)?

SLU‑PP‑332 is a synthetic small-molecule peptide-like compound developed at Saint Louis University School of Medicine. It functions as a potent pan-agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ), with highest affinity for ERRα (EC₅₀ ≈ 98 nM) [1]. In preclinical research, this compound mimics key effects of endurance exercise—such as enhanced energy metabolism, mitochondrial biogenesis, and fat oxidation—while not influencing estrogen receptor pathways.

Chemical Structure of SLU-PP-332 (60 capsules, 250MCG)

SLU‑PP‑332 is chemically designated as 4‑Hydroxy‑N’‑(2‑naphthylmethylene)benzohydrazide, with a molecular formula of C₁₈H₁₄N₂O₂ and molecular weight 290.3 Da, as documented in PubChem (CID 5404083) [1]. Its structure features a benzohydrazide core linked to a naphthalene moiety via a hydrazone bond (Z-configuration), a scaffold optimized for ERR receptor selectivity and pharmacologic stability [1][2].

What Are the Effects of SLU-PP-332 (60 capsules, 250MCG)?

Exercise‑Mimetic Metabolism:

In rodent models, SLU‑PP‑332 increases mitochondrial respiration (in vitro) and induces aerobic exercise gene signatures in muscle [3].

Energy Expenditure & Fat Loss:

Diet-induced obese mice showed increases in energy expenditure and fatty acid oxidation along with significant reductions in body fat tags, without appetite changes [4].

Insulin Sensitivity & Metabolic Health:

Obese and metabolic syndrome models reported improved glucose tolerance and insulin sensitivity following SLU‑PP‑332 treatment [4][5].

Enhanced Endurance:

Preclinical studies reveal a marked increase in exercise performance—augmenting time and distance running—attributable to enhanced mitochondrial capacity and muscle fiber oxidative profile [4].

Pan‑ERR Activation:

By activating ERRα, ERRβ, and ERRγ (EC₅₀ values ~98, 230, 430 nM respectively), SLU‑PP‑332 coordinates systemic energy regulation across tissues, especially high-energy organs like muscle, heart, and liver [4].

Citations

1. PubChem Compound Summary for SLU‑PP‑332 (CID 5404083): 4‑Hydroxy‑N’‑(2‑naphthylmethylene)benzohydrazide; formula C₁₈H₁₄N₂O₂; MW 290.3 Da.
2. Gatto GJ, Ao Z, Kearse MG, et al. “CREP‑1: A small‑molecule tool compound that selectively activates estrogen‑related receptor alpha (ERRα).” Cell Chem Biol. 2020;27(10):1259–1266. PMID: 32931536.
3. Kim DK, Ryu D, Jeong JH, et al. “Estrogen‑related receptors mediate SLU‑PP‑332–induced exercise gene expression and mitochondrial biogenesis.” Trends Pharmacol Sci. 2022;43(7):578‑591. PMID: 35672756.
4. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” J Pharmacol Exp Ther. 2023. (SLU‑PP‑332 increased energy expenditure, fatty acid oxidation, reduced fat mass, improved glucose tolerance in obese mice.)
5. Medical News Today summary of SLU‑PP‑332 preclinical data: exercise mimetic, weight loss, insulin sensitivity.